Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 18;11(1):6207.
doi: 10.1038/s41598-021-85395-z.

Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia

Maria A Barceló  1   2   3 , Mònica Povedano  4 , Juan F Vázquez-Costa  5   6   7 , Álvaro Franquet  8   9   10 , Marta Solans  8   9 , Marc Saez  8   9
Affiliations

Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia

Maria A Barceló et al. Sci Rep. .

Abstract

According to the degree of upper and lower motor neuron degeneration, motor neuron diseases (MND) can be categorized into amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS) or progressive muscular atrophy (PMA). Although several studies have addressed the prevalence and incidence of ALS, there is a high heterogeneity in their results. Besides this, neither concept has been previously studied in PLS or PMA. Thus, the objective of this study was to estimate the prevalence and incidence of MND, (distinguishing ALS, PLS and PMA), in the Spanish regions of Catalonia and Valencia in the period 2011-2019. Two population-based Spanish cohorts were used, one from Catalonia and the other from Valencia. Given that the samples that comprised both cohorts were not random, i.e., leading to a selection bias, we used a two-part model in which both the individual and contextual observed and unobserved confounding variables are controlled for, along with the spatial and temporal dependence. The prevalence of MND was estimated to be between 3.990 and 6.334 per 100,000 inhabitants (ALS between 3.248 and 5.120; PMA between 0.065 and 0.634; and PLS between 0.046 and 1.896), and the incidence between 1.682 and 2.165 per 100,000 person-years for MND (ALS between 1.351 and 1.754; PMA between 0.225 and 0.628; and PLS between 0.409-0.544). Results were similar in the two regions and did not differ from those previously reported for ALS, suggesting that the proposed method is robust and that neither region presents differential risk or protective factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Location of the Catalonia and Valencia regions.
Figure 2
Figure 2
(a) Forest plot of the estimated prevalence per 100,000 inhabitants in Catalonia and Valencia. (b) Forest plot of the estimated incidence per 100,000 person-years in Catalonia and Valencia.
Figure 3
Figure 3
(a) Map of the estimated prevalence per census tract across the study region (Catalonia). Own construction using the leaflet package, version 2.0.3 [https://CRAN.R-project.org/package=leaflet]. (b) Map of the estimated prevalence per census tract across the study region (Valencia). Own construction using the leaflet package, version 2.0.3 [https://CRAN.R-project.org/package=leaflet].
Figure 4
Figure 4
(a) Map of the estimated incidence per census tract across the study region (Catalonia). Own construction using the leaflet package, version 2.0.3 [https://CRAN.R-project.org/package=leaflet]. (b) Map of the estimated incidence per census tract across the study region (Valencia). Own construction using the leaflet package, version 2.0.3 [https://CRAN.R-project.org/package=leaflet].
See this image and copyright information in PMC

References

    1. Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;2:1182–1194. doi: 10.1016/S1474-4422(16)30199-5. - DOI - PubMed
    1. Turner, M.R., Talbot, K. Primary lateral sclerosis: diagnosis and management. Pract Neurol [Internet]. BMJ Publishing Group Ltd; 2020; Available from: https://pn.bmj.com/content/early/2020/03/25/practneurol-2019-002300 - PubMed
    1. Turner, M.R., Barohn, R.J., Corcia, P., Fink, J.K., Harms, M.B., Kiernan, M.C., et al. Primary lateral sclerosis: consensus diagnostic criteria. Ajroud-Driss, S., Andrews, J.A., Babu, S., Bede, P., Benatar, M., Chew, S., et al., editors. J Neurol Neurosurg Psychiatry [Internet]. BMJ Publishing Group Ltd; 2020;91:373–7. Available from: https://jnnp.bmj.com/content/91/4/373 - PMC - PubMed
    1. Gordon, P.H., Cheng, B., Katz, I.B., Pinto, M., Hays, A.P., Mitsumoto, H., et al. The natural history of primary lateral sclerosis. Neurology [Internet]. 2006;66:647 LP – 653. Available from: http://n.neurology.org/content/66/5/647.abstract - PubMed
    1. Visser J, de Jong JMBV, de Visser M. The history of progressive muscular atrophy: Syndrome or disease? Neurol. U.S. 2008;70:723–727. - PubMed

MeSH terms